2Cannon GP.Overcoming thrombolytic resistance. Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol, 1999,34:1395 - 402
3Gibson M, Cannon CP, Murphy SA,et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation, 2000,101: 125 - 30
4Shah A, Wagner GS, Granger GB, et al. Pragnostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST segment resolution analysis: reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol,2000,35: 666 - 72
5Christenson RH, Vollmer RT, Ohman EM, et al. Relation of temporol creatine kinase MB release and outcome after thrombolytic theray for acute myocardial infarction. Am J Cardiol, 2000,85: 543 - 7
6Vermeer F, Oude Ophuis AJM, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safely and feasibility study. Heart, 1999,82:426- 31
7Strategies for Patency Enhancement in the Emergency Deparment (SPEED) Group. Trial of Abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation, 2000, 101: 2788 - 94
8Juliard J-M, Himben D, Cristofini P, et al.A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. Am J Cardiol, 1999,83:305- 10
